May 14, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that ...

- Company on track to initiate Phase 2 trial evaluating sabirnetug in first half of 2024 CHARLOTTESVILLE, Va., March 21, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals (ABOS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Thomas Shrader from BTIG maintained a Buy rating on the stock and ...

Acumen Pharmaceuticals has dosed the first patient in ALTITUDE-AD, a Phase II trial designed to evaluate the clinical ...

Acumen Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.00025, expectations were $-0.23. Operator: Good ...

Arthur J. Gallagher & Co., headquartered in Rolling Meadows, Illinois, has expanded its reach by acquiring Acumen Advisors, Inc., an employee benefits company situated in Cedar Rapids.

Tactician par excellence Gautam Gambhir couldn't have envisaged a battle of brains with a more different kind of adversary ...

Good day and thank you for standing by. Welcome to Acumen Pharmaceuticals First Quarter 2024 Conference Call and Webcast. [Operator Instructions] Please be advised that today's conference is being ...

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted ...

The results build upon Acumen’s prior presentations at the AD/PD™ 2024 Annual Meeting and positive topline data first announced in July 2023, highlighting sabirnetug as the first humanized monoclonal ...